You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

17 search results for: disease progression

EAACI 2023 | Pediatric Type 2 Inflammatory <b>Disease</b> <b>Progression</b>

expert video

EAACI 2023 | Pediatric Type 2 Inflammatory Disease Progression

40 min

Type 2 Inflammation

Dr. Leonard Bacharier and Profs. Oscar Palomares and Stephan Weidinger explore shared features of type 2 pathophysiology in AD, asthma, and EoE, and disease burden in pediatric patients

expert video

Can Early Intervention Shape the Course of Atopic Dermatitis?

8 min

Dermatology

Dr. Paller presents highlights from recent clinical studies in AD, which highlight the potential benefits of early and effective AD treatment in modifying disease progression and mitigating atopic comorbidities.

Type 2 Inflammatory <b>Disease</b> Trajectories: Unraveling Patterns of <b>Disease</b> Development and Burden in Pediatric Patients

expert video

Type 2 Inflammatory Disease Trajectories: Unraveling Patterns of Disease Development and Burden in Pediatric Patients

15 min

Type 2 Inflammation

Dr. Leonard Bacharier presents potential disease trajectories and burden for pediatric patients with type 2 inflammatory diseases.

Exploring The Concept of <b>Disease</b> Modification in Atopic Dermatitis

expert video

Exploring The Concept of Disease Modification in Atopic Dermatitis

13 min

Dermatology

Exploring the concept of disease modification and related pathomechanisms in atopic dermatitis.

New Perspectives on <b>Disease</b> Modification in Atopic Dermatitis - Panel Discussion

expert video

New Perspectives on Disease Modification in Atopic Dermatitis - Panel Discussion

10 min

Dermatology

Panel discussion exploring what disease modification could involve in atopic dermatitis.

interactivity

Moderate Exacerbations

5 min

Pulmonology

Understand the impact of moderate chronic obstructive pulmonary disease (COPD) exacerbations on future exacerbation risk, lung function decline, mortality, and patient quality of life.

expert video

Can early intervention modify the course of AD?

5 min

Dermatology

Dr. Amy Paller emphasizes that early intervention in children can alter disease progression. Depending on the severity, this can be achieved with topical interventions or systemic therapies.

Type 2 Inflammation as the Common Thread in Multiple <b>Disease</b>s

videoanimation

Type 2 Inflammation as the Common Thread in Multiple Diseases

5 min

Type 2 Inflammation

This video highlights type 2 inflammation as the common thread that links AD, asthma, CRSwNP, and EoE.

Infographic

Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)

5 min

Dermatology

An infographic exploring the process of allergen sensitization and the impact it may have on the development of atopic comorbidities in children with AD.

expert video

Can Early Intervention Shape the Course of Atopic Dermatitis?

15 min

Dermatology

Exploring the concept of disease modification through early intervention with targeted systemic therapies in atopic dermatitis.

expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression

expert video

What Are the Key Inflammatory Processes in Patients with COPD?

2 min

Pulmonology

Dr. Klaus Rabe, MD, PhD, discusses the key inflammatory processes in patients with COPD and their implications for patient care.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: South KoreaChange country/region